These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12109305)

  • 1. [The treatment of chronic inflammatory diseases with monoclonal antibodies against tumor necrosis factor: side effects, contraindications and precautions].
    Derksen RH; Bijlsma JW
    Ned Tijdschr Geneeskd; 2002 Jun; 146(25):1165-8. PubMed ID: 12109305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.
    Fromont A; De Seze J; Fleury MC; Maillefert JF; Moreau T
    Cytokine; 2009 Feb; 45(2):55-7. PubMed ID: 19109035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF antibodies: lessons from the past, roadmap for the future.
    Shealy DJ; Visvanathan S
    Handb Exp Pharmacol; 2008; (181):101-29. PubMed ID: 18071943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-alpha blockade and tuberculosis: better look before you leap.
    Arend SM; Breedveld FC; van Dissel JT
    Neth J Med; 2003 Apr; 61(4):111-9. PubMed ID: 12852719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
    Feldmann M; Pusey CD
    J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
    Weisman MH
    J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
    Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
    Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
    Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor.
    Mueller RB; Skapenko A; Grunke M; Wendler J; Stuhlmuller B; Kalden JR; Schulze-Koops H
    Arthritis Rheum; 2005 Feb; 52(2):451-60. PubMed ID: 15692975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
    Slifman NR; Gershon SK; Lee JH; Edwards ET; Braun MM
    Arthritis Rheum; 2003 Feb; 48(2):319-24. PubMed ID: 12571839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review.
    Atzeni F; Sarzi-Puttini P; Doria A; Iaccarino L; Capsoni F
    Autoimmun Rev; 2005 Mar; 4(3):144-52. PubMed ID: 15823500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Apperceptive form visual agnosia caused by anti-TNFalpha therapy to rheumatoid arthritis].
    Kobayashi S; Tanno M; Nakamura I; Ito K; Ugawa Y
    Rinsho Shinkeigaku; 2007; 47(2-3):96-9. PubMed ID: 17511276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases.
    Taylor PC; Williams RO; Feldmann M
    Curr Opin Biotechnol; 2004 Dec; 15(6):557-63. PubMed ID: 15560982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.